Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is well-positioned for success with its strong focus on developing innovative mebufotenin therapies targeting the critical unmet need of TRD patients. With the recent FDA clearance for CMC and device, GH is on track for a late-2026 pivotal start for its Phase III trial, which has already been designed to closely match the robust efficacy demonstrated in their Phase IIb dataset. Additionally, the current positive landscape in the psychedelics space should provide additional tailwinds for GH Research's success.

Bears say

GH Research is facing significant competition in the development of mebufotenin therapies, specifically their lead product candidate GH001 for the treatment of treatment-resistant depression (TRD). In addition, challenges with clinical trials and the potential for slower than expected adoption in the market due to a different mode of administration could impact the company's commercial success. These factors, combined with limited financials and only one segment focused on research and development, suggest a negative outlook on GH Research's stock.

GHRS has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Buy consensus rating as of Aug 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.